Neil Fleshner

List of Publications by Citations

Source: https://exaly.com/author-pdf/9688366/neil-fleshner-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91 papers	1,700 citations	20 h-index	40 g-index
104 ext. papers	2,154 ext. citations	3.7 avg, IF	4.35 L-index

#	Paper	IF	Citations
91	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
90	Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. *Journal of Clinical Oncology*, **2013**, 31, 3069-75	2.2	210
89	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. *European Urology*, **2017**, 72, 665-674	10.2	98
88	Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. *Urology*, **2002**, 60, 93-7	1.6	98
87	Dietary fat and prostate cancer. *Journal of Urology*, **2004**, 171, S19-24	2.5	72
86	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. *European Urology*, **2019**, 75, 300-309	10.2	71
85	Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. *Contemporary Clinical Trials*, **2007**, 28, 763-9	2.3	63
84	Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. *Journal of Urology*, **2005**, 174, 636-41; discussion 641; quiz 801	2.5	52
83	Prostate cancer prevention: past, present, and future. *Cancer*, **2007**, 110, 1889-99	6.4	51
82	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. *European Urology*, **2020**, 77, 311-317	10.2	50
81	Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. *European Urology*, **2014**, 66, 619-22	10.2	43
80	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. *Journal of Molecular Diagnostics*, **2016**, 18, 395-406	5.1	40
79	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. *Canadian Urological Association Journal*, **2016**, 10, E16-30	1.2	39
78	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. *Canadian Urological Association Journal*, **2014**, 8, 24-7	1.2	38
77	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. *Epigenetics*, **2012**, 7, 1037-45	5.7	38
76	Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. *Scientific Reports*, **2014**, 4, 4432	4.9	33
75	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. *Histopathology*, **2019**, 74, 474-482	7.3	23

74	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. *European Urology Oncology*, **2018**, 1, 238-241	6.7	21
73	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2020**, 18, 343-350	3.3	20
72	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. *Journal of Urology*, **2018**, 199, 1182-1187	2.5	20
71	Epidemiology and Prevention of Prostate Cancer. *European Urology Oncology*, **2021**,	6.7	20
70	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. *Journal of Urology*, **2020**, 203, 1085-1093	2.5	20
69	A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. *Clinical Epigenetics*, **2018**, 10, 147	7.7	18
68	Quality indicators in the management of bladder cancer: A modified Delphi study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 328-334	2.8	16
67	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. *Oncology Letters*, **2017**, 14, 390-396	2.6	14
66	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. *Journal of Urology*, **2016**, 196, 1645-1650	2.5	14
65	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. *Oncotarget*, **2017**, 8, 25928-25941	3.3	12
64	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. *BJU International*, **2017**, 120, 76-82	5.6	11
63	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. *Journal of Urology*, **2020**, 204, 466-475	2.5	11
62	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. *Journal of Urology*, **2016**, 195, 307-12	2.5	9
61	Active surveillance in patients with a PSA >10 ng/mL. *Canadian Urological Association Journal*, **2014**, 8, E702-7	1.2	9
60	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 603.e17-603.e25	2.8	8
59	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. *World Journal of Urology*, **2020**, 38, 2547-2554	4	8
58	Germ Cell Testicular Tumors-Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. *Urology*, **2019**, 125, 8-19	1.6	8
57	Controversies in the management of testicular seminoma. *Urologic Oncology*, **2002**, 20, 227-33		7

56	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. *European Urology Oncology*, **2019**, 2, 231-238	6.7	7
55	Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. *Canadian Journal of Urology*, **2006**, 13 Suppl 3, 3-13	0.8	7
54	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. *Canadian Urological Association Journal*, **2020**, 14, E453-E457	1.2	6
53	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 240.e13-240.e20	2.8	6
52	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. *Canadian Urological Association Journal*, **2018**, 12, E281-E297	1.2	6
51	Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression. *Journal of Urology*, **2014**, 192, 1088-93	2.5	6
50	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 39.e1-39.e9	2.8	6
49	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. *European Urology Focus*, **2021**, 7, 537-545	5.1	5
48	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. *Journal of Urology*, **2020**, 204, 1187-1194	2.5	5
47	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. *Radiology*, **2021**, 300, 369-379	20.5	5
46	Defining high-risk prostate cancer: current status. *Canadian Journal of Urology*, **2005**, 12 Suppl 1, 14-7; discussion 94-6	0.8	5
45	Lynch Syndrome in Urologic Malignancies - What Does the Urologist Need to Know?. *Urology*, **2019**, 134, 24-31	1.6	4
44	Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. *Canadian Urological Association Journal*, **2020**, 14, 36-41	1.2	4
43	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients - A Cross Sectional Study. *Urology*, **2019**, 134, 154-162	1.6	4
42	Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. *Canadian Urological Association Journal*, **2015**, 9, E14-21	1.2	4
41	First Experiences with Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients. *Journal of Nuclear Medicine*, **2021**, 62, 975-978	8.9	4
40	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. *Journal of Urology*, **2020**, 204, 416-426	2.5	4
39	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. *Cancer*, **2021**, 127, 2587-2594	6.4	4

38	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. *Canadian Urological Association Journal*, **2016**, 10, E424-E427	1.2	4
37	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. *European Urology Oncology*, **2019**, 2, 88-96	6.7	3
36	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. *Journal of Urology*, **2019**, 202, 1159-1165	2.5	3
35	Is pathology necessary to predict mortality among men with prostate-cancer?. *BMC Medical Informatics and Decision Making*, **2014**, 14, 114	3.6	2
34	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, 131-131	2.2	2
33	A narrative review of pelvic lymph node dissection in prostate cancer. *Translational Andrology and Urology*, **2020**, 9, 3049-3055	2.3	2
32	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. *Journal of Urology*, **2020**, 204, 476-482	2.5	2
31	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. *JAMA Network Open*, **2021**, 4, e2114694	10.4	2
30	Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. *World Journal of Urology*, **2019**, 37, 799-804	4	2
29	Prostate cancer: chemoprevention update 2005. *Canadian Journal of Urology*, **2005**, 12 Suppl 2, 2-4	0.8	2
28	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. *Journal of Urology*, **2018**, 200, 1056-1061	2.5	1
27	Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review. *Canadian Urological Association Journal*, **2015**, 9, E671-2	1.2	1
26	. *Canadian Urological Association Journal*, **2009**, 3, 211-212	1.2	1
25	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (18F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 5553-5553	2.2	1
24	Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9. *European Urology*, **2021**, 81, e51-e51	10.2	1
23	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 622-629	6.2	1
22	Optimizing screening and management of cardiovascular health in prostate cancer: A review. *Canadian Urological Association Journal*, **2020**, 14, E458-E464	1.2	1
21	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. *European Urology Open Science*, **2020**, 21, 1-4	0.9	1

20	Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. *Canadian Urological Association Journal*, **2020**, 14, E115-E125	1.2	1
19	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 431.e1-431.e8	2.8	1
18	Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. *Proteomics - Clinical Applications*, **2009**, 3, 347-58	3.1	0
17	The role of metformin, statins and diet in men on active surveillance for prostate cancer. *World Journal of Urology*, **2021**, 1	4	0
16	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. *Canadian Urological Association Journal*, **2021** , 15, E545-E552	1.2	0
15	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. *Canadian Urological Association Journal*, **2021**, 15, E623-E629	1.2	0
14	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. *Urology*, **2021**, 153, 147-155	1.6	0
13	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.. *European Radiology*, **2022**, 1	8	0
12	Major role for 5-alpha reductase inhibitors in the aging male. *Canadian Urological Association Journal*, **2007**, 1, 22	1.2	
11	Reply by Authors. *Journal of Urology*, **2020**, 204, 475	2.5	
10	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. *UroOncology*, **2002**, 2, 93-94		
9	Editorial Comment. *Journal of Urology*, **2019**, 202, 504-505	2.5	
8	Reply by Authors. *Journal of Urology*, **2019**, 202, 1165	2.5	
7	Reply by Authors. *Journal of Urology*, **2020**, 203, 1093	2.5	
6	Reply by Authors. *Journal of Urology*, **2020**, 204, 1194	2.5	
5	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. *FASEB Journal*, **2012**, 26, 388.5	0.9	
4	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. *European Urology Focus*, **2021**, 7, 513-521	5.1	
3	AUTHOR REPLY. *Urology*, **2021**, 153, 155	1.6	

2	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. *Canadian Urological Association Journal*, **2019**, E292-E299	1.2
1	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 191.e17-191.e24	2.8